National Immunobiological Company (“Nacimbio”), member of Rostec State Corporation, Pharmstandard PJSC and Italian biopharmaceutical company Kedrion Biopharma have signed an agreement to establish JSC “Kirov Plasma”.

The joint venture will manage development and implementation of plasma-derived product manufacturing at the plant in Kirov. Pharmstandard holds 37.5% of the JV charter capital.

The agreement was signed in Rostec building in presence of Rostec CEO Sergey Chemezov and interim Governor of the Kirov Region Igor Vasiliev.

According to the Kirov Region Government, the draft framework agreement will be designed in Q3 2017. Regional Governor Igor Vasiliev told that launching of  plasma-derived product manufacturing in Kirov has strategic importance both for the Kirov Region and for the country in general.

The new enterprise will manufacture Albumin, Immunoglobulin, Coagulation Factors VIII and IX. The production output will fully satisfy the demand of the Russian healthcare system for such products.

As its full production capacity is reached, the plant shall annually process up to 600 tons of plasma.

“Our objective is to eliminate Russia’s dependence on imports of biologicals and pharmaceuticals. These days 100% of Coagulation Factors VIII and IX, vital for haemophiliacs, are imported. Total imports of plasma-derived products reach 90%. After the plant reaches its full capacity, the Russian healthcare system will be fully supplied with albumin, immunoglobulin, Coagulation Factors VIII and IX”, noted Nacimbio CEO Mariam Khubieva. The Company Press Service reminded that last December, Nacimbio signed the corresponding Memorandum of Understanding , under which Kedrion Biopharma would transfer its manufacturing Know-How and implement its quality control system, while Pharmstandard would co-invest the project.

“The plant in  Kirov was supposed to be commissioned already in 2009, but due to the certain financial and management issues, the project was frozen. I am certain that the joint efforts, competence and resources of Pharmstandard, Rostec and the Italian partners will ensure that the Kirov plant, which is of crucial importance for the Russian healthcare system, will be launched”, stressed Grigory Potapov, Pharmstandard CEO.